UBX Stock Overview
A biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Unity Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.26 |
| 52 Week High | US$3.10 |
| 52 Week Low | US$0.94 |
| Beta | 0.91 |
| 1 Month Change | 24.86% |
| 3 Month Change | 93.16% |
| 1 Year Change | 28.41% |
| 3 Year Change | -77.31% |
| 5 Year Change | -96.40% |
| Change since IPO | -98.64% |
Recent News & Updates
Recent updates
Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth?
Nov 05
Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?
Jul 12Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation
Mar 05Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky
Nov 18UNITY Biotechnology falls 7% on reverse stock split
Oct 19Unity Biotechnology cuts stock sales agreement in half to $25M
Aug 19Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M
Aug 12A Look At Unity's UBX1325 Phase 1 Results
Jul 26Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently
Dec 22A Look Inside Unity Bio's Transition To An Ophthalmology Company
Nov 27Shareholder Returns
| UBX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.6% | 3.5% | 0.6% |
| 1Y | 28.4% | 2.9% | 22.4% |
Return vs Industry: UBX exceeded the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: UBX exceeded the US Market which returned 22.4% over the past year.
Price Volatility
| UBX volatility | |
|---|---|
| UBX Average Weekly Movement | 20.8% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: UBX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: UBX's weekly volatility has increased from 12% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 19 | Anirvan Ghosh | unitybiotechnology.com |
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company’s lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications.
Unity Biotechnology, Inc. Fundamentals Summary
| UBX fundamental statistics | |
|---|---|
| Market cap | US$38.76m |
| Earnings (TTM) | -US$21.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs UBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UBX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$18.39m |
| Gross Profit | -US$18.39m |
| Other Expenses | US$3.50m |
| Earnings | -US$21.89m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did UBX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 00:00 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Unity Biotechnology, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Elemer Piros | Cantor Fitzgerald & Co. |
| Daniil Gataulin | Chardan Capital Markets, LLC |
| Yigal Nochomovitz | Citigroup Inc |